- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05850689
Studio di Lumateperone come terapia aggiuntiva nel trattamento di pazienti con disturbo depressivo maggiore
Uno studio multicentrico randomizzato, in doppio cieco, controllato con placebo per valutare l'efficacia e la sicurezza di Lumateperone come terapia aggiuntiva nel trattamento di pazienti con disturbo depressivo maggiore
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The study will be conducted in three periods:
- Screening Period (up to 2 weeks) during which patient eligibility will be assessed.
- Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42 mg/day in 1:1 ratio.
- Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Study Contact
- Numero di telefono: 844-434-4210
- Email: Participate-In-This-Study1@its.jnj.com
Luoghi di studio
-
-
-
Cherven Bryag, Bulgaria, 5980
- Reclutamento
- Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
-
Kardzhali, Bulgaria, 6600
- Reclutamento
- Medical Center Lifemed
-
Pleven, Bulgaria, 5800
- Reclutamento
- Medical Center Medconsult-Pleven
-
Plovdiv, Bulgaria, 4004
- Reclutamento
- Medical Center Mentalcare OOD
-
Sofia, Bulgaria, 1680
- Reclutamento
- Medical Center Intermedica, OOD
-
Sofia, Bulgaria, 1510
- Reclutamento
- Medical Center Hera EOOD
-
Sofia, Bulgaria, 1202
- Reclutamento
- MHC - Sofia, EOOD
-
Sofia, Bulgaria, 1431
- Terminato
- University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD
-
Stara Zagora, Bulgaria, 6003
- Completato
- UMHAT Prof. Dr. St. Kirkovich AD
-
Varna, Bulgaria, 9020
- Reclutamento
- Diagnostic Consulting Center Mladost - M Varna
-
-
-
-
-
Douai, Francia, 59500
- Reclutamento
- Cabinet Medical des Drs Prizac-Desbonnet Scottez
-
Nantes, Francia, 44093
- Reclutamento
- CHU de Nantes hotel Dieu
-
Nîmes, Francia, 30029
- Reclutamento
- Hopital Caremeau
-
Paris, Francia, 75012
- Reclutamento
- Groupe Hospitalier Pitie-Salpetriere
-
Poitiers, Francia, 86021
- Reclutamento
- CH Henri Laborit
-
-
-
-
-
Ahmedabad, India, 380008
- Sospeso
- Ratandeep Surgical Hospital And Endoscopy Clinic
-
Ahmedabad, India, 380009
- Sospeso
- Sushrusha Navneet Memorial Hospital
-
Ajmer, India, 305001
- Sospeso
- J L N Medical College and Attached Hospitals
-
Bikaner, India, 334001
- Reclutamento
- S P Medical College And Associated Group of Hospitals
-
Bārāmati, India, 413102
- Reclutamento
- Baramati Hospital
-
Chandigarh, India, 160012
- Reclutamento
- Post Graduate Institute of Medical Education And Research PGIMER
-
Guwahati, India, 781032
- Completato
- Gauhati Medical College and Hospital
-
Kolhāpur, India, 416001
- Reclutamento
- Swastik Hospital
-
Nagpur, India, 440001
- Reclutamento
- KIMS-Kingsway Hospitals
-
Palsāna, India, 394315
- Reclutamento
- Divyam Hospital
-
Pune, India, 411011
- Reclutamento
- Shree Samarth Hospital
-
Rajkot, India, 360001
- Completato
- Nagecha Hospital
-
Wardha, India, 442004
- Sospeso
- Acharya vinoba bhave rural hospital
-
-
-
-
-
Kaunas, Lituania, LT-44279
- Completato
- Romuvos Klinika, JSC
-
Ziegzdriai, Lituania, 53136
- Completato
- Kaunas Hospital of Lithuanian University of Health Sciences Psychiatric Clinic Mariu division
-
-
-
-
-
Belgrade, Serbia, 11000
- Reclutamento
- University Clinical Center of Serbia
-
Belgrade, Serbia, 11000
- Reclutamento
- Institute of Mental Health Serbia
-
Belgrade, Serbia, 11000
- Reclutamento
- Clinical Center Dr Dragisa Misovic Dedinje
-
Kovin, Serbia, 26220
- Reclutamento
- Special Hospital for Psychiatric Diseases Kovin
-
Kragujevac, Serbia, 34000
- Reclutamento
- University Clinical Center Kragujevac
-
Kragujevac, Serbia, 34000
- Reclutamento
- University Clinical Center Kragujevac 1
-
Niš, Serbia, 18000
- Reclutamento
- University Clinical Center NIS 1
-
Niš, Serbia, 18000
- Reclutamento
- University Clinical Center NIS
-
Novi Kneževac, Serbia, 23330
- Reclutamento
- Special Hospital for Psychiatric Diseases Sveti Vracevi
-
-
-
-
-
Barcelona, Spagna, 08036
- Reclutamento
- Hosp. Clinic de Barcelona
-
Barcelona, Spagna, 08035
- Reclutamento
- Hosp Univ Vall D Hebron
-
Madrid, Spagna, 28034
- Completato
- Hosp. Univ. Ramon Y Cajal
-
Sabadell, Spagna, 08208
- Reclutamento
- Hosp.Univ.Parc Tauli
-
Zamora, Spagna, 49021
- Reclutamento
- Hosp. Prov. de Zamora
-
-
-
-
Alabama
-
Huntsville, Alabama, Stati Uniti, 35801
- Reclutamento
- University of Alabama at Birmingham
-
-
California
-
Pico Rivera, California, Stati Uniti, 90660
- Reclutamento
- CNRI-Los Angeles, LLC
-
-
Connecticut
-
Farmington, Connecticut, Stati Uniti, 06030
- Reclutamento
- University of Connecticut Health Center
-
-
Florida
-
Clermont, Florida, Stati Uniti, 34711
- Terminato
- Vertex Clinical Research
-
Hialeah, Florida, Stati Uniti, 33012
- Sospeso
- New Life Medical Research Center, Inc.
-
Miami, Florida, Stati Uniti, 33122
- Reclutamento
- Premier Clinical Research Institute
-
Miami, Florida, Stati Uniti, 33137
- Reclutamento
- Miami Jewish Health System
-
Tampa, Florida, Stati Uniti, 33629
- Reclutamento
- Interventional Psychiatry of Tampa Bay
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30329
- Reclutamento
- The Emory Clinic
-
Decatur, Georgia, Stati Uniti, 30030
- Reclutamento
- CenExeli Research LLC
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- Terminato
- University of Kansas Medical Center Research Institute
-
Overland Park, Kansas, Stati Uniti, 66210
- Reclutamento
- Collective Medical Research
-
-
Massachusetts
-
Methuen, Massachusetts, Stati Uniti, 01844
- Terminato
- ActivMed Practices and Research
-
-
Missouri
-
O'Fallon, Missouri, Stati Uniti, 63368
- Reclutamento
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, Stati Uniti, 08755
- Reclutamento
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, Stati Uniti, 11235
- Reclutamento
- SPRI Clinical Trials, LLC
-
New York, New York, Stati Uniti, 10036
- Reclutamento
- Manhattan Behavioral Medicine
-
-
Ohio
-
Avon Lake, Ohio, Stati Uniti, 44012
- Reclutamento
- Quest Therapeutics of Avon Lake
-
Cincinnati, Ohio, Stati Uniti, 45219
- Reclutamento
- University of Cincinnati Medical Center
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- The Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- University of Pennsylvania - Perelman School of Medicine
-
-
Texas
-
Houston, Texas, Stati Uniti, 77081
- Reclutamento
- DM Clinical Research
-
Mansfield, Texas, Stati Uniti, 76063
- Completato
- Hawkins Psychiatry, PC
-
Richardson, Texas, Stati Uniti, 75080
- Reclutamento
- Pillar Clinical Research, LLC
-
-
Washington
-
Bellevue, Washington, Stati Uniti, 98007
- Reclutamento
- Northwest Clinical Research Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Male or female patients between the ages of 18 and 65 years, inclusive;
-
Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria:
- The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening;
- Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
- Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline;
- Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline;
- Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.
-
Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:
- citalopram/escitalopram
- fluoxetine
- paroxetine
- sertraline
- duloxetine
- levomilnacipran/milnacipran (if locally approved for MDD)
- venlafaxine/desvenlafaxine
- bupropion
- vilazodone
- vortioxetine
Exclusion Criteria:
-
Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
- Bipolar Disorder;
-
Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:
- Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment;
- Eating disorder;
- Substance use disorders (excluding nicotine);
- Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
- Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
-
The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;
-
The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;
-
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:
- At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
- At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
- At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
- The patient is considered to be in imminent danger to him/herself or others.
-
The patient has a first MDE at age 60 years or older.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore placebo: Placebo
|
Matching capsules administered orally, once daily |
|
Sperimentale: Lumateperone 42 mg
|
Lumateperone 42 mg capsules administered orally, once daily |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Montgomery-Asberg Depression Rating Scale
Lasso di tempo: Day 43
|
The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms. |
Day 43
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Clinical Global Impression Scale-Severity
Lasso di tempo: Day 43
|
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). |
Day 43
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Intra-Cellular Therapies, Inc. Clinical Trial, Intra-Cellular Therapies, Inc.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ITI-007-505
- ITI-007-505 (Altro identificatore: Janssen Research & Development, LLC)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .